Spray-type cannabidiol hemostatic and preparation method thereof

Abstract

The invention provides a spray-type cannabidiol hemostatic and a preparation method thereof. The hemostatic comprises a sprayable solution, and cannabidiol, a blood coagulation factor and an anti-inflammatory drug which are dispersed in the sprayable solution. The cannabidiol accounts for 0.05%-0.5% by mass of the sprayable solution, the blood coagulation factor accounts for 1%-5% by mass of the sprayable solution, and the anti-inflammatory drug accounts for 1%-5% by mass of the sprayable solution. The sprayable solution comprises water and glycerin accounting for 10%-20% of the mass of the water. According to the hemostatic agent, a layer of protective film with hemostatic, anti-inflammatory and analgesic effects can be quickly formed on the surface of a wound through synergistic cooperation of all the materials, operation is easy and convenient, the wound can be treated in the first time, and the infection risk is reduced. The hemostatic is suitable for emergency hemostasis and anti-inflammation scenes, such as outdoor injury and traffic accident scenes.

Description

TECHNICAL FIELD

[0001] The application belongs to the technical field of hemostatic agents, and particularly relates to a spray type cannabidiol hemostatic agent and a preparation method thereof. BACKGROUND

[0002] In daily life and accidents, wound bleeding is a common situation, and rapid and effective hemostasis and subsequent anti-inflammatory treatment are crucial for wound healing and reducing the risk of infection. There are many types of hemostatic products on the market, mainly including hemostatic bandages, hemostatic powder, hemostatic gel and the like, but these products have many limitations in actual application.

[0003] For example, the hemostatic bandage can quickly block blood flow, but is only suitable for large hemorrhage of limbs, and long-term use can easily lead to tissue necrosis of the limbs, and the application scene is limited. The hemostatic powder needs to be directly sprinkled on the surface of the wound, and secondary damage to the wound is easy to occur during the operation process, and the powder is easy to fly and is difficult to accurately act on the wound. The hemostatic gel can form a covering layer on the surface of the wound, but the flowability of the gel is relatively strong, and it is difficult to maintain stable coverage in irregular wounds or easily rubbed parts, and the hemostatic speed and anti-inflammatory effect still need to be improved.

[0004] Therefore, it is necessary to improve the traditional hemostatic agent. SUMMARY

[0005] The application aims to overcome the defects of the prior art, such as limited application scene, inconvenient operation, single function, poor stability and low safety, and provide a spray type cannabidiol hemostatic agent and a preparation method thereof. The hemostatic agent can quickly form a protective film on the surface of the wound, realize the synergistic effect of hemostasis, anti-inflammatory and analgesia, and is simple and convenient to operate, high in stability, strong in safety, and suitable for various emergency hemostasis and anti-inflammatory scenes.

[0006] A spray type cannabidiol hemostatic agent comprises a sprayable solution and cannabidiol, coagulation factors and anti-inflammatory drugs dispersed in the sprayable solution, the mass percentage of the cannabidiol in the sprayable solution is 0.05%-0.5%, the mass percentage of the coagulation factors in the sprayable solution is 1%-5%, the mass percentage of the anti-inflammatory drugs in the sprayable solution is 1%-5%, and the sprayable solution comprises water and glycerol with a mass percentage of 10%-20% in water.

[0007] Optionally, the coagulation factors are at least one of prothrombin complex and fibrinogen.

[0008] Optionally, the anti-inflammatory drugs are at least one of ibuprofen, diclofenac sodium and aspirin.

[0009] Optionally, the sprayable cannabidiol hemostatic agent further comprises a stabilizer, wherein the stabilizer is at least one of vitamin C and sodium sulfite, and the mass percentage of the stabilizer in the sprayable solution is 0.1%-0.3%.

[0010] Optionally, the sprayable cannabidiol hemostatic agent further comprises a pH regulator, wherein the pH regulator is at least one of citric acid and sodium hydroxide, and the pH value of the sprayable solution is 6.5-7.5.

[0011] Optionally, the mass percentage of glycerol in the sprayable solution is 15%-18% relative to water.

[0012] Optionally, the mass percentage of cannabidiol in the sprayable solution is 0.1%-0.3%.

[0013] Optionally, the mass percentage of the coagulation factor in the sprayable solution is 2%-4%.

[0014] Optionally, the mass percentage of the anti-inflammatory drug in the sprayable solution is 2%-4%.

[0015] A preparation method of the sprayable cannabidiol hemostatic agent, comprising the following steps: S1: slowly adding glycerol into water, stirring at a stirring speed of 30-40°C and 300-500 r / min for 10-15 min to obtain a sprayable solution; S2: adding a stabilizer into the sprayable solution obtained in step S1, stirring at a stirring speed of 30-40°C and 400-600 r / min for 8-12 min until the stabilizer is completely dispersed; S3: adjusting the temperature of the sprayable solution obtained in step S2 to 25-30°C, adding a coagulation factor, and stirring at a stirring speed of 25-30°C and 500-700 r / min for 15-20 min to uniformly disperse the coagulation factor; S4: adding an anti-inflammatory drug into the sprayable solution obtained in step S3, and stirring at a stirring speed of 25-30°C and 400-600 r / min for 10-15 min until the anti-inflammatory drug is completely dispersed; S5: adding cannabidiol into the sprayable solution obtained in step S4, and stirring at a stirring speed of 25-30°C and 600-800 r / min for 20-25 min to uniformly disperse the cannabidiol; S6: adding a pH regulator into the sprayable solution obtained in step S5, adjusting the pH value of the solution to 6.5-7.5, and stirring at a stirring speed of 25-30°C and 300-500 r / min for 5-8 min to obtain a mixed solution; S7: The mixed solution obtained in step S6 is filtered with a filter precision of 0.22 μm, and then the filtered solution is filled into a spray bottle and sealed, thereby obtaining the spray-type cannabidiol hemostatic agent.

[0016] Advantages In the present application, the basic composition of the spray-type cannabidiol hemostatic agent and the synergistic cooperation of the main components ensure that the solution has suitable spray performance. The synergistic effect of cannabidiol, coagulation factors and anti-inflammatory drugs can quickly form a protective film with hemostatic, anti-inflammatory and analgesic effects on the surface of the wound. The operation is simple, the wound can be treated in the first time, the risk of infection is reduced, and it is suitable for various emergency hemostasis and anti-inflammatory scenes. DETAILED DESCRIPTION

[0017] An embodiment of the present application provides a spray-type cannabidiol hemostatic agent, which comprises a sprayable solution and cannabidiol, coagulation factors and anti-inflammatory drugs dispersed in the sprayable solution. The mass percentage of cannabidiol in the sprayable solution is 0.05%-0.5%, the mass percentage of coagulation factors in the sprayable solution is 1%-5%, and the mass percentage of anti-inflammatory drugs in the sprayable solution is 1%-5%. The sprayable solution comprises water and glycerol with a mass percentage of 10%-20% in water. In the hemostatic agent, the basic composition of the spray-type cannabidiol hemostatic agent and the synergistic cooperation of the main components ensure that the solution has suitable spray performance. The synergistic effect of cannabidiol, coagulation factors and anti-inflammatory drugs can quickly form a protective film with hemostatic, anti-inflammatory and analgesic effects on the surface of the wound. The operation is simple, the wound can be treated in the first time, the risk of infection is reduced, and it is suitable for various emergency hemostasis and anti-inflammatory scenes.

[0018] The core role of glycerol is viscosity control and moisturizing film formation. After 10%-20% glycerol is mixed with water, the solution can form suitable surface tension, so that the droplet size during spraying is 50-60 μm, which is suitable for the shape of the wound. At the same time, glycerol has strong moisturizing property, and can quickly form a transparent and continuous protective film on the surface of the wound. This film is not only a physical barrier (isolating external bacteria and reducing the risk of infection), but also a sustained-release carrier for other active ingredients, avoiding the loss of effectiveness due to volatilization or loss of components.

[0019] The role of water is solvent and dispersion medium. As a polar solvent, water can uniformly disperse coagulation factors and anti-inflammatory drugs. Through staged stirring (such as stirring cannabidiol at 600-800 r / min), the problem of low solubility of cannabidiol (liposoluble) is solved, and all active ingredients are uniformly dispersed and dissolved, providing a prerequisite for subsequent action on the wound.

[0020] Coagulation factors (1%-5%): Select prothrombin complex, fibrinogen, etc., which can be rapidly converted into fibrin after contacting with blood to form a coagulation layer under the protective film to achieve hemostasis in a short time, and to gain a window period for anti-inflammatory and analgesic components to avoid continuous bleeding of the wound leading to inflammation spreading.

[0021] Anti-inflammatory drugs (1%-5%): Select ibuprofen, diclofenac sodium, etc. non-steroidal drugs to quickly relieve wound pain by blocking prostaglandin synthesis, while reducing redness and inflammation to avoid interference with the coagulation effect of inflammation reaction.

[0022] Cannabidiol (0.05%-0.5%): As a plant-derived active ingredient, it can inhibit chronic inflammation by regulating CB2 receptors, make up for the shortcoming of anti-inflammatory drugs, enhance the analgesic effect of anti-inflammatory drugs, and avoid skin irritation of traditional hemostatic agents.

[0023] In some embodiments, the coagulation factor is at least one of prothrombin complex and fibrinogen. Prothrombin complex and fibrinogen can quickly activate the coagulation reaction, improve the hemostatic speed, and have high stability, wide sources, and are easy to mix with other components, ensuring the stability and producibility of the product. At the same time, prothrombin complex and fibrinogen can quickly stop bleeding, providing time for cannabidiol and anti-inflammatory drugs to play an anti-inflammatory and analgesic role, and the anti-inflammatory effect of cannabidiol can reduce the influence of inflammation reaction on the coagulation effect in the coagulation process, and the three components synergistically improve the overall effect of hemostasis and inflammation. The compatibility of such coagulation factors with the sprayable solution ensures that the sprayability of the solution is not affected.

[0024] In some embodiments, the anti-inflammatory drug is at least one of ibuprofen, diclofenac sodium, and aspirin. Ibuprofen, diclofenac sodium, and aspirin have anti-inflammatory and analgesic effects, good water solubility, can be uniformly dispersed in the sprayable solution, quickly act on the inflammatory site of the wound, relieve pain and inflammation, and improve the user experience. Ibuprofen and other drugs can quickly relieve acute inflammation and pain, and cannabidiol has long-acting anti-inflammatory effect, and the combination of the two can achieve rapid and persistent anti-inflammatory and analgesic effect. At the same time, such anti-inflammatory drugs have good compatibility with coagulation factors and do not affect the hemostatic function of coagulation factors. After mixing with the sprayable solution, the sprayability of the solution is not affected, ensuring the stable play of the overall function of the product.

[0025] In some embodiments, the hemostatic agent further comprises 0.1%-0.3% of a stabilizing agent by mass percentage of the sprayable solution; and the stabilizing agent is at least one of vitamin C and sodium sulfite. The stabilizing agent can effectively prevent cannabidiol, coagulation factors, and anti-inflammatory drugs from being oxidized and degraded during storage and use, prolong the shelf life of the product, ensure the activity of each active ingredient when acting on the wound, and improve the stability and effectiveness of the product.

[0026] In some embodiments, the hemostatic agent further includes a pH adjuster; the pH adjuster is at least one of citric acid and sodium hydroxide; the pH value of the sprayable solution is 6.5-7.5. The activity of the active ingredients in the hemostatic agent is easily affected by pH value, and an unsuitable solution pH value can easily irritate the wound. The addition of a pH adjuster can solve these problems, allowing each active ingredient to maintain high activity in a suitable pH environment, ensuring the full exertion of hemostatic, anti-inflammatory, and analgesic effects, while reducing wound irritation and improving safety. The pH adjuster has good compatibility with other components, does not affect the spray performance of the solution or the synergistic effect between the components, and achieves a balance between functionality and safety in the product.

[0027] In some embodiments, the glycerol content in the sprayable solution is 15%-18% by mass of water. This content range allows the sprayable solution to have a more suitable viscosity and surface tension, ensuring the formation of uniform, fine droplets during spraying to accurately cover the wound surface. At the same time, glycerol has a stronger moisturizing effect, which can better retain moisture in the protective film formed on the wound surface and promote wound healing.

[0028] In some embodiments, cannabidiol accounts for 0.1%-0.3% of the mass of the sprayable solution. This content range allows cannabidiol to fully exert its anti-inflammatory and analgesic effects without causing skin irritation or other adverse reactions due to excessive content, thus achieving a balance between anti-inflammatory and analgesic effects and safety.

[0029] In some embodiments, the coagulation factor accounts for 2%-4% of the mass of the sprayable solution. Within this dosage range, the coagulation factor can rapidly activate the coagulation reaction, achieving efficient hemostasis.

[0030] In some embodiments, the anti-inflammatory drug accounts for 2%-4% of the mass of the sprayable solution. This content can quickly relieve acute inflammation and pain in wounds without causing adverse reactions such as gastrointestinal irritation or skin allergies due to excessive content, achieving an optimal balance between anti-inflammatory and analgesic effects and safety. It complements the anti-inflammatory pathway of cannabidiol, enhancing the anti-inflammatory effect; simultaneously, this content has no antagonistic effect with clotting factors, does not affect the hemostatic function of clotting factors, and can be evenly dispersed in the sprayable solution, precisely covering the wound with the spray, achieving a three-in-one protective effect of hemostasis, anti-inflammation, and analgesia.

[0031] Another embodiment of the present invention provides a method for preparing the above-mentioned spray-type cannabidiol hemostatic agent, comprising the following steps: S1: Slowly add glycerin to water and stir for 10-15 minutes at 30-40℃ and 300-500r / min to obtain a sprayable solution.

[0032] S2: Add the stabilizer to the sprayable solution obtained in step S1, and stir at 30-40℃ and 400-600r / min for 8-12 minutes until the stabilizer is completely dispersed.

[0033] S3: Adjust the temperature of the sprayable solution obtained in step S2 to 25-30℃, add the coagulation factor, and stir for 15-20 minutes at 25-30℃ and a stirring speed of 500-700r / min to ensure that the coagulation factor is evenly dispersed.

[0034] S4: Add the anti-inflammatory drug to the sprayable solution obtained in step S3, and stir for 10-15 minutes at 25-30℃ and 400-600r / min until the anti-inflammatory drug is completely dispersed.

[0035] S5: Add cannabidiol to the sprayable solution obtained in step S4, and stir for 20-25 minutes at 25-30℃ and 600-800r / min to ensure uniform dispersion of cannabidiol.

[0036] S6: Add a pH adjuster to the sprayable solution obtained in step S5 to adjust the pH value of the solution to 6.5-7.5, and stir for 5-8 minutes at 25-30℃ and 300-500r / min to obtain a mixed solution.

[0037] S7: Filter the mixed solution obtained in step S6 with a filtration accuracy of 0.22 μm, then put the filtered solution into a spray bottle and seal it to obtain the final product.

[0038] In the above preparation method, temperature, stirring speed and time are controlled in stages to ensure that each component is evenly dispersed and maintains its activity. At the same time, filtration and sealed packaging ensure product purity and stability, reduce the risk of component degradation during production, and improve product qualification rate and shelf life.

[0039] Furthermore, the sprayable solution is prepared at 30-40℃: this avoids denaturation of subsequently added clotting factors due to high temperatures when glycerol is mixed with water (the inventors discovered that the activity of prothrombin complexes significantly decreases at temperatures above 40℃). The active ingredient is added at 25-30℃: this temperature range is the stable temperature zone for cannabidiol and anti-inflammatory drugs, thus avoiding degradation of the ingredients due to high temperatures.

[0040] Furthermore, in the above preparation method, the easily soluble components (glycerin, anti-inflammatory drugs) are dispersed first, and then the poorly soluble components (cannabidiol) are dispersed: by gradually increasing the stirring speed (from 300-500 r / min to 600-800 r / min), the local anti-inflammatory failure caused by cannabidiol aggregation is avoided.

[0041] Furthermore, 0.22μm filtration removes undispersed particles (such as cannabidiol microcrystals) to avoid secondary damage to the wound; the sealed spray bottle packaging prevents the solution from evaporating and causing an increase in glycerol concentration, while also extending the shelf life.

[0042] The following are examples and comparative examples.

[0043] Example 1 The preparation steps of the hemostatic agent in this embodiment are as follows: S1: Slowly add glycerol to water and stir for 12 minutes at 35℃ and 400 rpm to obtain a sprayable solution. The mass percentage of glycerol in water is 15%.

[0044] S2: Add 0.2% by mass of vitamin C stabilizer to the sprayable solution obtained in step S1, and stir at 35°C and 500 r / min for 10 min until the stabilizer is completely dispersed.

[0045] S3: Adjust the temperature of the sprayable solution obtained in step S2 to 30°C, add 3% by mass of the prothrombin complex of the coagulation factor, and stir for 18 minutes at 30°C and 600 r / min to make the coagulation factor evenly dispersed.

[0046] S4: Add 3% by mass of the anti-inflammatory drug ibuprofen to the sprayable solution obtained in step S3, and stir at 30°C and 500 r / min for 12 min until the anti-inflammatory drug is completely dispersed.

[0047] S5: Add 0.1% by mass of cannabidiol to the sprayable solution obtained in step S4, and stir at 30°C and 700 r / min for 22 min to ensure uniform dispersion of cannabidiol.

[0048] S6: Add citric acid, a pH adjuster, to the sprayable solution obtained in step S5 to adjust the pH value of the solution to 6.8, and stir for 5 minutes at 30℃ and 400r / min to obtain a mixed solution.

[0049] S7: Filter the mixed solution obtained in step S6 with a filtration accuracy of 0.22 μm, then put the filtered solution into a spray bottle and seal it to obtain the final product.

[0050] Example 2 Compared with Example 1, the differences are as follows: glycerol accounts for 18% of the mass of water, cannabidiol accounts for 0.3% of the mass of the sprayable solution, coagulation factors account for 4% of the mass of the sprayable solution, anti-inflammatory drugs account for 2% of the mass of the sprayable solution, and stabilizers account for 0.3% of the mass of the sprayable solution. The stirring temperature in S1 is 40°C and the stirring speed is 500 r / min; the stirring speed in S3 is 700 r / min; and the stirring speed in S5 is 800 r / min.

[0051] Example 3 Compared with Example 1, the differences are as follows: glycerol accounts for 16% of the mass of water, cannabidiol accounts for 0.2% of the mass of the sprayable solution, coagulation factors account for 2% of the mass of the sprayable solution, anti-inflammatory drugs account for 5% of the mass of the sprayable solution, and stabilizers account for 0.1% of the mass of the sprayable solution. The stirring temperature in S1 is 32°C and the stirring speed is 350 r / min; the stirring speed in S3 is 550 r / min; and the stirring speed in S5 is 650 r / min.

[0052] Comparative Example 1 The difference from Example 1 is that it does not contain cannabidiol.

[0053] Comparative Example 2 The difference compared to Example 1 is that the coagulation factor accounts for 6% of the mass of the sprayable solution.

[0054] Comparative Example 3 The difference compared to Example 1 is that the glycerol accounts for 8% of the water by mass.

[0055] Comparative Example 4 The difference compared to Example 1 is that it does not contain stabilizers.

[0056] Comparative Example 5 Compared with Example 1, the difference is that the preparation method is as follows: all components are added to deionized water at one time, stirred at 25°C and 500r / min for 30min, filtered with a filtration accuracy of 0.22μm, and then the filtered solution is put into a spray bottle and sealed to obtain the final product.

[0057] Test case (1) Hemostasis time A rabbit ear vein slit model was established, with a slit depth of 2 mm and a length of 5 mm. 0.5 mL of spray was applied to the wound surface for each sample, and the timing was recorded until bleeding completely stopped. Five rabbits were used in each group, and the average value was taken.

[0058] (2) Anti-inflammatory effect A rat dorsal scald inflammation model was established by scalding the rat with 80℃ hot water for 10 seconds, resulting in a 1cm diameter red and swollen wound. Each group of samples was sprayed twice daily with 0.3mL of hot water each time for 3 consecutive days. The diameter of the scalded area was measured, and the scald reduction rate was calculated. Reduction rate = (initial scald diameter - post-test scald diameter) / initial scald diameter × 100%. Five rats were used in each group, and the average value was taken.

[0059] (3) Analgesic effect A mouse hot plate analgesia model was established, with the hot plate temperature set at 55℃ ± 0.5℃. 0.2 mL of sample was applied to the right hind paw of each mouse. The pain threshold (mouse licking time) was recorded before application and at 15 min, 30 min, and 60 min after application. A pain rating scale (0-4 points, 0 points for no pain, 4 points for severe pain) was used. Five mice were used in each group, and the average value was taken.

[0060] (4) Storage stability Accelerated storage was performed at 40℃ and 75% relative humidity for 30 days. The retention rate of cannabidiol was determined using high-performance liquid chromatography (HPLC). Retention rate = (content after storage / initial content) × 100%.

[0061] (5) Skin irritation Intact skin irritation test in rabbits. Apply 0.5 mL of the sample to the hairless area on the back of the rabbit, cover with gauze, and observe the skin erythema and edema after 24 hours. Score the irritation response (0-8 points, 0 points for no irritation, 8 points for severe irritation).

[0062]

[0063] As can be seen from the table above: (1) The hemostasis time of Examples 1-3 was <30s, the redness and swelling reduction rate was >80%, the pain score was <1, the cannabidiol retention rate was >90%, and the skin irritation score was 0, indicating that the formulation and preparation method of the present invention can achieve the effects of rapid hemostasis, efficient anti-inflammatory and safe analgesia, and has low skin irritation and long storage time.

[0064] (2) Comparative Example 1 (without cannabidiol): prolonged hemostasis time, reduced redness and swelling reduction rate by more than 50%, and significantly increased pain score, proving that cannabidiol is crucial for anti-inflammatory and analgesic effects and synergistic hemostasis.

[0065] (3) Comparative Example 2 (excessive coagulation factor): Although hemostasis was accelerated, the retention rate of cannabidiol was significantly reduced, and skin irritation occurred, proving that the coagulation factor content needs to be strictly controlled.

[0066] (4) Comparative Example 3 (too low glycerol): The hemostasis time was significantly prolonged, proving that glycerol plays a key role in spray performance and protective film formation.

[0067] (5) Comparative Example 4 (without stabilizer): The cannabidiol retention rate decreased significantly, indicating that stabilizer is an important factor in ensuring storage stability.

[0068] (6) Comparative Example 5 (conventional preparation): The hemostasis time was prolonged and the anti-inflammatory and analgesic effects were reduced, proving that the phased preparation method of the present invention can ensure the activity and uniformity of the components.

[0069] The above description is merely a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

[0070] For those skilled in the art, based on the ideas of this invention, there will be changes in the specific implementation methods and application scope. Therefore, the content of this specification should not be construed as a limitation of this invention.

Claims

1. A spray-on cannabidiol hemostatic agent, characterized in that, The solution includes a sprayable solution and cannabidiol, a clotting factor, and an anti-inflammatory drug dispersed in the sprayable solution. The cannabidiol accounts for 0.05%-0.5% of the mass of the sprayable solution, the clotting factor accounts for 1%-5% of the mass of the sprayable solution, and the anti-inflammatory drug accounts for 1%-5% of the mass of the sprayable solution. The sprayable solution includes water and glycerol accounting for 10%-20% of the mass of water.

2. The spray-on cannabidiol hemostatic agent as described in claim 1, characterized in that, The coagulation factor is at least one of prothrombin complex and fibrinogen.

3. The spray-on cannabidiol hemostatic agent as described in claim 1, characterized in that, The anti-inflammatory drug is at least one of ibuprofen, diclofenac sodium, and aspirin.

4. The spray-on cannabidiol hemostatic agent as described in claim 1, characterized in that, It also includes a stabilizer comprising 0.1%-0.3% by mass of the sprayable solution; the stabilizer is at least one of vitamin C and sodium sulfite.

5. The spray-on cannabidiol hemostatic agent as described in claim 1, characterized in that, It also includes a pH adjuster; the pH adjuster is at least one of citric acid and sodium hydroxide; the pH value of the sprayable solution is 6.5-7.

5.

6. The spray-on cannabidiol hemostatic agent according to any one of claims 1-5, characterized in that, The sprayable solution contains 15%-18% glycerol by mass of water.

7. The spray-on cannabidiol hemostatic agent according to any one of claims 1-5, characterized in that, The cannabidiol accounts for 0.1%-0.3% of the mass of the sprayable solution.

8. The spray-on cannabidiol hemostatic agent according to any one of claims 1-5, characterized in that, The coagulation factor accounts for 2%-4% of the mass of the sprayable solution.

9. The spray-on cannabidiol hemostatic agent according to any one of claims 1-5, characterized in that, The anti-inflammatory drug accounts for 2%-4% of the mass of the sprayable solution.

10. A method for preparing a spray-on cannabidiol hemostatic agent as described in any one of claims 1-9, characterized in that, Includes the following steps: S1: Slowly add glycerin to water and stir for 10-15 minutes at 30-40℃ and 300-500r / min to obtain a sprayable solution; S2: Add the stabilizer to the sprayable solution obtained in step S1, and stir at 30-40℃ and 400-600r / min for 8-12 minutes until the stabilizer is completely dispersed. S3: Adjust the temperature of the sprayable solution obtained in step S2 to 25-30℃, add coagulation factor, and stir for 15-20 minutes at 25-30℃ and a stirring speed of 500-700r / min to make the coagulation factor evenly dispersed. S4: Add the anti-inflammatory drug to the sprayable solution obtained in step S3, and stir for 10-15 minutes at 25-30℃ and 400-600r / min until the anti-inflammatory drug is completely dispersed. S5: Add cannabidiol to the sprayable solution obtained in step S4, and stir for 20-25 minutes at 25-30℃ and 600-800r / min to make the cannabidiol evenly dispersed. S6: Add a pH adjuster to the sprayable solution obtained in step S5 to adjust the pH value of the solution to 6.5-7.5, and stir for 5-8 minutes at 25-30℃ and 300-500r / min to obtain a mixed solution; S7: Filter the mixed solution obtained in step S6 with a filtration accuracy of 0.22 μm, then put the filtered solution into a spray bottle and seal it to obtain the final product.

Images